Immunocore Holdings plc (IMCR): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMCR POWR Grades
- Sentiment is the dimension where IMCR ranks best; there it ranks ahead of 99.14% of US stocks.
- IMCR's strongest trending metric is Stability; it's been moving down over the last 179 days.
- IMCR's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).
IMCR Stock Summary
- IMCR's went public 1.15 years ago, making it older than merely 0.64% of listed US stocks we're tracking.
- With a price/sales ratio of 35.65, Immunocore Holdings plc has a higher such ratio than 95.05% of stocks in our set.
- As for revenue growth, note that IMCR's revenue has grown -13.12% over the past 12 months; that beats the revenue growth of only 9.4% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Immunocore Holdings plc, a group of peers worth examining would be PROF, NVTA, SRNE, POWI, and TXG.
- Visit IMCR's SEC page to see the company's official filings. To visit the company's web site, go to www.immunocore.com.
IMCR Stock Price Chart Interactive Chart >
IMCR Price/Volume Stats
| Current price | $28.65 | 52-week high | $42.25 |
| Prev. close | $27.46 | 52-week low | $18.43 |
| Day low | $26.33 | Volume | 103,500 |
| Day high | $28.87 | Avg. volume | 181,844 |
| 50-day MA | $31.64 | Dividend yield | N/A |
| 200-day MA | $31.45 | Market Cap | 1.26B |
Immunocore Holdings plc (IMCR) Company Bio
Immunocore Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops and commercializes a new generation of transformative medicines to address unmet needs in cancer, infection, and autoimmune diseases. Immunocore Holdings serves customers in the United Kingdom and the United States.
Latest IMCR News From Around the Web
Below are the latest news stories about Immunocore Holdings plc that investors may wish to consider to help them evaluate IMCR as an investment opportunity.
Immunocore to present at the SVB Leerink Global Healthcare ConferenceImmunocore to present at the SVB Leerink Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 February 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in the virtual 11th Ann |
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA DatesAfter a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. About 3 new molecular entities, or NMEs, were approved during the month, including Immunocore Holdings plc''s (NASDAQ: IMCR ) Kimmtrak for certain patients with advanced eye melanoma and Pfizer, Inc.''s (NYSE: PFE ) atopic dermatitis treatment Cibinqo. NME approval is an important indicator to measure innovation in drug research. NME approvals totaled 50 in 2021, almost equaling the numbers of the previous year. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN )- Sanofi (NASDAQ: SNY ), however, failed to get the nod for expanding the Libtayo label to include cervical cancer. Pfizer also faced rejection for its pediatric growth hormone deficiency treatment Somatrogon. A PDUFA date ... |
Immunocore soars 17% as FDA approves Kimmtrak for uveal melanomaImmunocore''s (IMCR) medicine Kimmtrak (tebentafusp-tebn) was approved by the U.S |
Immunocore gets FDA approval for cell therapy targeting melanomaKimmtrak is the first T cell receptor therapeutic, and first treatment for metastatic uveal melanoma, approved by the federal agency. Immunocore, a British biotech firm, has U.S. operations in Conshohocken. |
FDA Approves First T Cell Receptor Therapy From Immunocore For Eye CancerThe FDA has approved Immunocore Holdings plc (NASDAQ: IMCR) (tebentafusp-tebn) for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). Marketed as Kimmtrak, approval highlighting a series of firsts: First TCR therapeutic to receive FDA approval, First bispecific T cell engager to receive FDA approval to treat a solid tumor. The first and only therapy for unresectable or metastatic uveal melanoma to be approved by the FDA. Related: Immunocore Tebentafusp Show |
IMCR Price Returns
| 1-mo | -14.14% |
| 3-mo | 26.94% |
| 6-mo | -20.66% |
| 1-year | -30.12% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -16.33% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...